Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
71,309.73 +4,186.39 (+6.24%) CMC Crypto 200
1,538.11 +49.56 (+3.33%)
OCGN Jan 2025 1.500 call
| Previous close | 0.8700 |
| Open | 0.9500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.8400 - 0.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2k |
GlobeNewswireOcugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada. “I’m very pleased to present OC
- GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
- GuruFocus.com
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.
